drugset / Trial / NCT03494712

Safety of Single Intravenous Administration of S95010 in Human Healthy Volunteers

NCT03494712 ↗

Phase 1 Completed 49 enrolled Servier ADIR, a Servier Group company · collab
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of the study is to assess, the safety and tolerability of single ascending doses of S 95010 and to assess the pharmacokinetics (PK) of S 95010.

Timeline

Start
2018-02-21
Primary completion
2019-04-10
Completion
2019-04-10

Drugs

EvaluationDrugModalityDoseRoute
Subject S 95010 Unknown — Intravenous